1-12 of 12
Surender Juneja
Close
Sort by
Journal Articles

Pseudo–Chédiak-Higashi inclusions in BCR::ABL1 -like B-lymphoblastic leukemia with IGH::EPOR rearrangement

Rithin Nedumannil, Surender Juneja
Journal: Blood
Blood (2022) 139 (10): 1598.
https://doi.org/10.1182/blood.2021014726
Published: 2022
Journal Articles

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Max Wolf, FRACP, FRCPA, MBBS, Surender Juneja, MD, David Alan Westerman, MBBS, FRCPA, FRACP, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1876.
https://doi.org/10.1182/blood-2018-99-114048
Published: 2018
Journal Articles

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Clinical Trials & Observations
Mary Ann Anderson, Constantine Tam, Thomas E. Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David C. S. Huang, John F. Seymour, Andrew W. Roberts
Journal: Blood
Blood (2017) 129 (25): 3362–3370.
https://doi.org/10.1182/blood-2017-01-763003
Published: 2017
Includes: Supplemental data
Journal Articles

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Thomas E Lew, Mary Ann Anderson, MBBS, Constantine S. Tam, MBBS, David C.S. Huang, MBBS, MRCP, PhD, Surender Juneja, MD FRCPA, David A Westerman, MBBS, FRACP, FRCPA, John F Seymour, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 3223.
https://doi.org/10.1182/blood.V128.22.3223.3223
Published: 2016
Journal Articles

CD19 Negative Relapse in B-ALL Treated with Blinatumomab Therapy: Avoiding the Trap

Costas K Yannakou, MBBS(Hons), Neil Came, MBBS, FRACP, FRCPA, Ashish R Bajel, MBBS, FRACP, FRCPA, Surender Juneja, MD FRCPA
Journal: Blood
Blood (2015) 126 (23): 4983.
https://doi.org/10.1182/blood.V126.23.4983.4983
Published: 2015
Journal Articles

Diffuse large B-cell lymphoma in leukemic phase with flower cell morphology

Eric Wong, Surender Juneja
Journal: Blood
Blood (2014) 123 (22): 3378.
https://doi.org/10.1182/blood-2014-03-559088
Published: 2014
Journal Articles

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Mary Ann Anderson, MBBS, FRACP, FRCPA, Constantine C.S. Tam, MBBS, FRACP, FRCPA, John F. Seymour, MBBS FRACP, Anthony Bell, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Surender Juneja, MD, David C.S. Huang, MB, BS, MRCP, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2013) 122 (21): 1304.
https://doi.org/10.1182/blood.V122.21.1304.1304
Published: 2013
Journal Articles

Comparison of Cytochemistry, Flow Cytometry and Immunohistochemistry for the Detection of Myeloperoxidase in Acute Myeloid Leukemia.

Linda Saravanan, MBBS, Surender Juneja, MBBS/MD/FRCPA
Journal: Blood
Blood (2007) 110 (11): 4256.
https://doi.org/10.1182/blood.V110.11.4256.4256
Published: 2007
Journal Articles

CD 138 Immunostaining of Bone Marrow Trephine Specimens Is the Most Sensitive Method for Quantifying Marrow Involvement in Patients with Plasma Cell Dyscrasias.

Ashley P. Ng, MBBS B Med Sci, Andrew Wei, M.B.BS, P.H.D., Dinesh Bhurani, M.B.BS, Peter Chappell, Frank Feleppa, Surender Juneja, M.B.BS MD(Path).
Journal: Blood
Blood (2005) 106 (11): 5071.
https://doi.org/10.1182/blood.V106.11.5071.5071
Published: 2005
Journal Articles

Pax-5 Demonstrates Residual B-Cells in Bone Marrow Trephines Post Anti-CD20 Immunotherapy.

Alwyn D’Souza, MB, ChB, FRACP, Surender Juneja, MBBS, MD, FRCPA, Melanie Trivett, Dennis Carney, MBBS, FRACP, FRCPA, David Westerman, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2005) 106 (11): 5013.
https://doi.org/10.1182/blood.V106.11.5013.5013
Published: 2005
Journal Articles

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

Clinical Trials & Observations
Kenneth F. Bradstock, Jane P. Matthews, Raymond M. Lowenthal, Heather Baxter, John Catalano, Timothy Brighton, Devinder Gill, Paul Eliadis, Douglas Joshua, Paul Cannell, Anthony P. Schwarer, Simon Durrant, Anne Gillett, Jerry Koutts, Kerry Taylor, John Bashford, Christopher Arthur, Arno Enno, Lindsay Dunlop, Jeff Szer, Michael Leahy, Surender Juneja, Graham A. R. Young, for the Australasian Leukaemia and Lymphoma Group
Journal: Blood
Blood (2005) 105 (2): 481–488.
https://doi.org/10.1182/blood-2004-01-0326
Published: 2005
Journal Articles

Altered Multidrug Resistance Phenotype Caused by Anthracycline Analogues and Cytosine Arabinoside in Myeloid Leukemia

Xiu F. Hu, Alison Slater, Phillip Kantharidis, Danny Rischin, Surender Juneja, Ralph Rossi, Grace Lee, John D. Parkin, John R. Zalcberg
Journal: Blood
Blood (1999) 93 (12): 4086–4095.
https://doi.org/10.1182/blood.V93.12.4086
Published: 1999